1
|
Xie X, Liu X, Li R, Fan L, Huang F. ω‑3 fatty acids in atherosclerotic cardiovascular disease (Review). Biomed Rep 2024; 20:94. [PMID: 38765861 PMCID: PMC11099599 DOI: 10.3892/br.2024.1782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 04/11/2024] [Indexed: 05/22/2024] Open
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is one of the most common chronic diseases in the world. Epidemiological evidence and clinical trials have shown that ω-3 fatty acids have a variety of promoting effects in reducing the risk of ASCVD, but different conclusions of large randomized controlled trials make their clinical use in the prevention and treatment of ASCVD controversial. The present review focuses on the pharmacological mechanism, clinical trials and evidence value of clinical applications of ω-3 fatty acids in order to provide theoretical and practical evidence for the clinical application strategy, and follow-up research and development of ω-3 fatty acids as anti-ASCVD drugs.
Collapse
Affiliation(s)
- Xingxing Xie
- Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
| | - Xue Liu
- Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
| | - Rong Li
- Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
| | - Ling Fan
- Clinical Trial Center for Drugs and Medical Devices, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
| | - Fujing Huang
- Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
| |
Collapse
|
2
|
Song Y, Wang Q, Jia L. Omega-3 fatty acids and their influence on hypertension and coronary atherosclerosis: Insights from a Mendelian randomization approach. J Clin Hypertens (Greenwich) 2024; 26:382-390. [PMID: 38450969 PMCID: PMC11007784 DOI: 10.1111/jch.14782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 01/14/2024] [Accepted: 01/16/2024] [Indexed: 03/08/2024]
Abstract
It has been suggested that Omega-3 fatty acids may improve endothelial thickness and thereby reduce the onset of cardiovascular diseases such as coronary atherosclerosis and hypertension. However, published observational epidemiological studies on the relationship between cardiovascular disease (CVD) and Omega-3 fatty acids remain inconclusive. Here, we performed a two-sample Mendelian randomisation analysis using publicly available GWAS pooled statistics to study a GWAS dataset of 16 380 466 SNPs in 23 363 cases and 195 429 controls (also of European ancestry) to determine genetic susceptibility to hypertension. We performed random-effects Inverse Variance Weighted (IVW) Mendelian Randomization (MR) analyses supplemented by a series of sensitivity assessments to measure the robustness of the findings and to detect any violations of the MR assumptions. During the course of the study, we used IVW, MR-Egger, and weighted median regression to infer that Omega-3 intake has a potentially adverse effect against atherosclerosis, although the trend was not significant (OR = 1.1198; 95%; CI: 0.9641-1.3006, p = .130). Meanwhile, our analyses showed a statistically significant negative association between Omega-3 fatty acid levels and risk of hypertension (OR = 0.9006; 95% CI: 0.8179-0.9917, p = .033). In addition, we explored the causal relationship between atherosclerosis and hypertension and found a significant correlation (OR = 1.3036; 95% CI: 1.0672-1.5923, p = .009). In conclusion, our extensive data investigated by MR suggest that elevated levels of Omega-3 fatty acids may be associated with an decreased risk of hypertension. Although there is no direct link between hypertension and atherosclerosis, the possibility of a subtle association cannot be categorically excluded.
Collapse
Affiliation(s)
- Yuchen Song
- College of Integrated Chinese and Western MedicineLiaoning University of Traditional Chinese MedicineShenyangLiaoningChina
| | - Qun Wang
- Key Laboratory of Ministry of Education for TCM Viscera‐State Theory and ApplicationsMinistry of Education of ChinaLiaoning University of Traditional Chinese MedicineShenyangLiaoningChina
| | - Lianqun Jia
- Key Laboratory of Ministry of Education for TCM Viscera‐State Theory and ApplicationsMinistry of Education of ChinaLiaoning University of Traditional Chinese MedicineShenyangLiaoningChina
| |
Collapse
|
3
|
Backes JM, Hilleman DE. Lipid lowering therapy: implications of recent clinical trials. Future Cardiol 2024; 20:89-98. [PMID: 38226457 DOI: 10.2217/fca-2023-0132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 12/21/2023] [Indexed: 01/17/2024] Open
Abstract
Recent lipid lowering therapy trials have provided important insights on certain agents while also continuing to expand our understanding of atherosclerotic cardiovascular disease (ASCVD) risk. Findings from current trials include the impact of statin therapy on ASCVD among populations with HIV, the benefit of lowering low-density lipoprotein cholesterol with bempedoic acid among patients considered statin intolerant, the safety and efficacy of inclisiran over a 4-year period, another failed attempt for fibrates to reduce ASCVD risk, which omega-3 fatty to utilize for lowering cardiovascular events, 'n-of-1' trials evaluating statin intolerance, and how low-dose rosuvastatin compared with commonly utilized supplements for lowering lipid parameters. Such data help inform so clinicians can optimize lipid lowering therapy and improve ASCVD outcomes.
Collapse
Affiliation(s)
- James M Backes
- Clinical & Medical Center Affairs, University of Kansas Medical Center, KU School of Pharmacy, Department of Pharmacy Practice, 2010 Becker Drive, Lawrence, KS 66047, USA
| | - Daniel E Hilleman
- Creighton University School of Pharmacy & Health Professions, 2500 California Plaza, Omaha, NE 68178, USA
| |
Collapse
|
4
|
Koeder C, Perez-Cueto FJA. Vegan nutrition: a preliminary guide for health professionals. Crit Rev Food Sci Nutr 2022; 64:670-707. [PMID: 35959711 DOI: 10.1080/10408398.2022.2107997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Since the beginning of the 21st century, interest in vegan diets has been rapidly increasing in most countries. Misconceptions about vegan diets are widespread among the general population and health professionals. Vegan diets can be health-promoting and may offer certain important advantages compared to typical Western (and other mainstream) eating patterns. However, adequate dietary sources/supplements of nutrients of focus specific to vegan diets should be identified and communicated. Without supplements/fortified foods, severe vitamin B12 deficiency may occur. Other potential nutrients of focus are calcium, vitamin D, iodine, omega-3 fatty acids, iron, zinc, selenium, vitamin A, and protein. Ensuring adequate nutrient status is particularly important during pregnancy, lactation, infancy, and childhood. Health professionals are often expected to be able to provide advice on the topic of vegan nutrition, but a precise and practical vegan nutrition guide for health professionals is lacking. Consequently, it is important and urgent to provide such a set of dietary recommendations. It is the aim of this article to provide vegan nutrition guidelines, based on current evidence, which can easily be communicated to vegan patients/clients, with the goal of ensuring adequate nutrient status in vegans.
Collapse
Affiliation(s)
- Christian Koeder
- Institute of Food Science and Human Nutrition, Leibniz University Hanover, Hanover, Germany
- Department of Nutrition, University of Applied Sciences Münster, Münster, Germany
| | | |
Collapse
|
5
|
Wiggins BS, Backes JM, Hilleman D. Statin-associated muscle symptoms-A review: Individualizing the approach to optimize care. Pharmacotherapy 2022; 42:428-438. [PMID: 35388918 DOI: 10.1002/phar.2681] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 03/03/2022] [Accepted: 03/08/2022] [Indexed: 12/12/2022]
Abstract
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as "statins" are considered first-line pharmacologic therapy for reducing low-density lipoprotein cholesterol (LDL-C). They have been demonstrated efficacy in a variety of patients populations to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Like any pharmacologic therapy, however, they are not without possible adverse effects that can lead to discontinuation, thus leading to a loss of benefit. The most common side effect related to statin therapy impacting compliance is musculoskeletal related, commonly referred to as statin-associated muscle systems (SAMS). While the overall incidence is relatively low, the consequences of nonadherence to statin therapy can have a negative impact on patient care. Therefore, it is important for healthcare providers to understand risk factors, how to diagnose, and how to manage this unfortunate adverse effect in order to optimize care.
Collapse
Affiliation(s)
- Barbara S Wiggins
- Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA
| | - James M Backes
- University of Kansas School of Pharmacy, Lawrence, Kansas, USA
| | - Daniel Hilleman
- Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska, USA
| |
Collapse
|
6
|
Drenjančević I, Pitha J. Omega-3 Polyunsaturated Fatty Acids-Vascular and Cardiac Effects on the Cellular and Molecular Level (Narrative Review). Int J Mol Sci 2022; 23:ijms23042104. [PMID: 35216214 PMCID: PMC8879741 DOI: 10.3390/ijms23042104] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/10/2022] [Accepted: 02/11/2022] [Indexed: 12/16/2022] Open
Abstract
In the prevention and treatment of cardiovascular disease, in addition to the already proven effective treatment of dyslipidemia, hypertension and diabetes mellitus, omega-3 polyunsaturated fatty acids (n-3 PUFAs) are considered as substances with additive effects on cardiovascular health. N-3 PUFAs combine their indirect effects on metabolic, inflammatory and thrombogenic parameters with direct effects on the cellular level. Eicosapentaenoic acid (EPA) seems to be more efficient than docosahexaenoic acid (DHA) in the favorable mitigation of atherothrombosis due to its specific molecular properties. The inferred mechanism is a more favorable effect on the cell membrane. In addition, the anti-fibrotic effects of n-3 PUFA were described, with potential impacts on heart failure with a preserved ejection fraction. Furthermore, n-3 PUFA can modify ion channels, with a favorable impact on arrhythmias. However, despite recent evidence in the prevention of cardiovascular disease by a relatively high dose of icosapent ethyl (EPA derivative), there is still a paucity of data describing the exact mechanisms of n-3 PUFAs, including the role of their particular metabolites. The purpose of this review is to discuss the effects of n-3 PUFAs at several levels of the cardiovascular system, including controversies.
Collapse
Affiliation(s)
- Ines Drenjančević
- Institute and Department of Physiology and Immunology, Faculty of Medicine Osijek, University Josip Juraj Strossmayer, Osijek J. Huttlera 4, HR-31000 Osijek, Croatia;
- Scientific Centre of Excellence for Personalized Health Care, University Josip Juraj Strossmayer Osijek, Trg Sv. Trojstva 3, HR-31000 Osijek, Croatia
| | - Jan Pitha
- Laboratory for Atherosclerosis Research, Center for Experimental Research, Department of Cardiology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
- Correspondence:
| |
Collapse
|
7
|
Lima Rocha JÉ, Mendes Furtado M, Mello Neto RS, da Silva Mendes AV, Brito AKDS, Sena de Almeida JOC, Rodrigues Queiroz EI, de Sousa França JV, Silva Primo MG, Cunha Sales ALDC, Gomes Vasconcelos A, Felix Cabral W, Souza Kückelhaus SA, de Souza de Almeida Leite JR, Fortes Lustosa AKM, Lucarini M, Durazzo A, Arcanjo DDR, Martins MDCDCE. Effects of Fish Oil Supplementation on Oxidative Stress Biomarkers and Liver Damage in Hypercholesterolemic Rats. Nutrients 2022; 14:nu14030426. [PMID: 35276784 PMCID: PMC8839313 DOI: 10.3390/nu14030426] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 01/13/2022] [Accepted: 01/14/2022] [Indexed: 01/27/2023] Open
Abstract
Metabolic syndrome, especially its component related to dyslipidemia, is related to the development of nonalcoholic fatty liver disease (NAFLD), which is a disease with a significant global prevalence. Supplementation with omega-3 polyunsaturated fatty acids emerged as a complementary therapeutic possibility for dyslipidemia, but its benefits are questioned. This paper aims at evaluating the effects of fish oil supplementation in rats with hypercholesterolemia induced by hypercholesterolemic diet (HD). The study design is based on an experimental model in which the animals were randomly divided into 3 groups: G1 (standard commercial feed + saline solution); G2 (hypercholesterolemic diet + saline solution) and G3 (hypercholesterolemic diet + fish oil) over a period of 16 weeks. Metabolic control parameters and oxidative stress biomarkers were evaluated according to standardized methodologies. The G3 group showed significantly lower values of plasma concentrations of TG, and hepatic myeloperoxidase as well as higher erythrocyte superoxide dismutase activity (p < 0.05). Regarding histopathological analysis, there was lipid accumulation in the liver of animals from group G2; meanwhile, hepatocytes reorganization and expressive reduction of lipid vacuoles and hepatic TG content was observed in group G3. This study demonstrated how fish oil supplementation reduced the plasma concentration and hepatic content of triglycerides, as well as liver tissue damage in histopathological analysis.
Collapse
Affiliation(s)
- Joana Érica Lima Rocha
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Mariely Mendes Furtado
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Renato Sampaio Mello Neto
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Ana Victória da Silva Mendes
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Ana Karolinne da Silva Brito
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - José Otávio Carvalho Sena de Almeida
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Emerson Iuri Rodrigues Queiroz
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - José Vinícius de Sousa França
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Maísa Guimarães Silva Primo
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Ana Lina de Carvalho Cunha Sales
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Andreanne Gomes Vasconcelos
- Research Center in Morphology and Applied Immunology, Faculty of Medicine, University of Brasília, Brasília 70910-900, Brazil; (A.G.V.); (W.F.C.); (S.A.S.K.); (J.R.d.S.d.A.L.)
| | - Wanessa Felix Cabral
- Research Center in Morphology and Applied Immunology, Faculty of Medicine, University of Brasília, Brasília 70910-900, Brazil; (A.G.V.); (W.F.C.); (S.A.S.K.); (J.R.d.S.d.A.L.)
| | - Selma Aparecida Souza Kückelhaus
- Research Center in Morphology and Applied Immunology, Faculty of Medicine, University of Brasília, Brasília 70910-900, Brazil; (A.G.V.); (W.F.C.); (S.A.S.K.); (J.R.d.S.d.A.L.)
| | - José Roberto de Souza de Almeida Leite
- Research Center in Morphology and Applied Immunology, Faculty of Medicine, University of Brasília, Brasília 70910-900, Brazil; (A.G.V.); (W.F.C.); (S.A.S.K.); (J.R.d.S.d.A.L.)
| | | | - Massimo Lucarini
- CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy; (M.L.); (A.D.)
| | - Alessandra Durazzo
- CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy; (M.L.); (A.D.)
| | - Daniel Dias Rufino Arcanjo
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
| | - Maria do Carmo de Carvalho e Martins
- Department of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil; (J.É.L.R.); (M.M.F.); (R.S.M.N.); (A.V.d.S.M.); (A.K.d.S.B.); (J.O.C.S.d.A.); (E.I.R.Q.); (J.V.d.S.F.); (M.G.S.P.); (A.L.d.C.C.S.); (D.D.R.A.)
- Correspondence:
| |
Collapse
|
8
|
Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, Gąsior M, Jankowski P, Jóźwiak J, Kłosiewicz-Latoszek L, Kowalska I, Małecki M, Prejbisz A, Rakowski M, Rysz J, Solnica B, Sitkiewicz D, Sygitowicz G, Sypniewska G, Tomasik T, Windak A, Zozulińska-Ziółkiewicz D, Cybulska B. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17:1447-1547. [PMID: 34900032 PMCID: PMC8641518 DOI: 10.5114/aoms/141941] [Citation(s) in RCA: 84] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 11/03/2021] [Indexed: 12/18/2022] Open
Abstract
In Poland there are still nearly 20 million individuals with hypercholesterolaemia, most of them are unaware of their condition; that is also why only ca. 5% of patients with familial hypercholesterolaemia have been diagnosed; that is why other rare cholesterol metabolism disorders are so rarely diagnosed in Poland. Let us hope that these guidelines, being an effect of work of experts representing 6 main scientific societies, as well as the network of PoLA lipid centers being a part of the EAS lipid centers, certification of lipidologists by PoLA, or the growing number of centers for rare diseases, with a network planned by the Ministry of Health, improvements in coordinated care for patients after myocardial infarction (KOS-Zawał), reimbursement of innovative agents, as well as introduction in Poland of an effective primary prevention program, will make improvement in relation to these unmet needs in diagnostics and treatment of lipid disorders possible.
Collapse
Affiliation(s)
- Maciej Banach
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland
- Cardiovascular Research Center, University of Zielona Gora, Zielona Gora, Poland
- Department of Cardiology and Congenital Diseases of Adults, Polish Mother’s Memorial Hospital Research Institute (PMMHRI) in Lodz, Lodz, Poland
| | - Paweł Burchardt
- Department of Hypertensiology, Angiology, and Internal Medicine, K. Marcinkowski Poznan University of Medical Science, Poznan, Poland
- Department of Cardiology, Cardiovascular Unit, J. Strus Hospital, Poznan, Poland
| | - Krzysztof Chlebus
- First Department and Chair of Cardiology, Medical University of Gdansk, Gdansk, Poland
| | - Piotr Dobrowolski
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
| | - Dariusz Dudek
- Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
| | - Krzysztof Dyrbuś
- 3 Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland; Silesian Center for Heart Diseases in Zabrze, Poland
| | - Mariusz Gąsior
- 3 Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland; Silesian Center for Heart Diseases in Zabrze, Poland
| | - Piotr Jankowski
- Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
- Department of Cardiology and Arterial Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
| | - Jacek Jóźwiak
- Department of Family Medicine and Public Health, Institute of Medical Sciences, Faculty of Medicine, University of Opole, Opole, Poland
| | | | - Irina Kowalska
- Department of Internal Medicine and Metabolic Diseases, Medical University of Bialystok, Bialystok, Poland
| | - Maciej Małecki
- Department and Chair of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland
| | - Aleksander Prejbisz
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
| | - Michał Rakowski
- Department of Molecular Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Jacek Rysz
- Chair of Nephrology, Arterial Hypertension, and Family Medicine, Medical University of Lodz, Lodz, Poland
| | - Bogdan Solnica
- Chair of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland
| | - Dariusz Sitkiewicz
- Department of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, Warsaw, Poland
| | - Grażyna Sygitowicz
- Department of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, Warsaw, Poland
| | - Grażyna Sypniewska
- Department of Laboratory Medicine, L. Rydygier Medical College in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
| | - Tomasz Tomasik
- Chair of Family Medicine, Jagiellonian University Medical College, Krakow, Poland
| | - Adam Windak
- Chair of Family Medicine, Jagiellonian University Medical College, Krakow, Poland
| | - Dorota Zozulińska-Ziółkiewicz
- Department and Chair of Internal Medicine and Diabetology, K. Marcinkowski Poznan University of Medical Sciences, Poznan, Poland
| | - Barbara Cybulska
- National Institute of Public Health NIH – National Research Institute, Warsaw, Poland
| |
Collapse
|